{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:58:24Z","timestamp":1781344704191,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Knappschaftskrankenhaus Bochum GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ruxolitinib, a JAK1\/JAK2 inhibitor, has demonstrated efficacy in achieving hematocrit control, spleen volume reductions, and symptom improvement in patients with polycythaemia vera (PV) resistant to or intolerant of hydroxyurea in clinical trials. PaVe is a prospective, noninterventional study of patients with PV who received ruxolitinib in a real-world setting in Germany.\u00a0Observational parameters included effectiveness, safety, patient satisfaction and quality of life. Patients with and without prior treatment with ruxolitinib were included in this study. Additionally, patients were stratified by no\/high risk. The study was primarily analyzed using descriptive methods.\u00a0Four hundred and thirty-three patients with PV were included in this study, of which 62% were pretreated with a JAK-inhibitor and 38% were not. Mean decreases from Baseline in hematocrit levels\/leukocyte counts at the last assessment were more pronounced in na\u00efve patients (-6.2% versus \u2212\u20091.6%\/-4.5\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l versus \u2212\u20091.4\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l) and high-risk patients (-6.3% versus \u2212\u20095.3%\/-4.8\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l versus \u2212\u20092.6\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l). Mean decreases from Baseline in thrombocyte counts at the last assessment were more pronounced in na\u00efve patients (-80.5\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l versus \u2212\u200942.6\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l) and no-risk patients (-108.0\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l versus \u2212\u200977.1\u2009\u00d7\u200910\n                    <jats:sup>3<\/jats:sup>\n                    \/\u00b5l). There was almost no difference in the total number of thromboembolic events in JAK inhibitor na\u00efve versus JAK inhibitor pretreated patients (3.1%, n\u2009=\u20095 versus 3.8%, n\u2009=\u200910). No new safety concerns were observed with ruxolitinib.\u00a0Findings from this study in a real-world setting show that ruxolitinib is an effective and safe second-line treatment in PV patients.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06947-9","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:59:03Z","timestamp":1778565543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera \u2013 German real-world data (PaVe study)"],"prefix":"10.1007","volume":"105","author":[{"given":"Martin","family":"Griesshammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyck","family":"von der Heyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Schlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi","family":"Weniger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koenigsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Stauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"G\u00fcckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"20","key":"6947_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"6","key":"6947_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ et al (2014) How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol 89(6):581\u2013587. https:\/\/doi.org\/10.1002\/ajh.23690","journal-title":"Am J Hematol"},{"issue":"3","key":"6947_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1517\/14728214.2013.832754","volume":"18","author":"R Tibes","year":"2013","unstructured":"Tibes R, Mesa RA (2013) Emerging drugs for polycythemia vera. Expert Opin Emerg Drugs 18(3):393\u2013404. https:\/\/doi.org\/10.1517\/14728214.2013.832754","journal-title":"Expert Opin Emerg Drugs"},{"issue":"13","key":"6947_CR4","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","volume":"100","author":"JL Spivak","year":"2002","unstructured":"Spivak JL (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100(13):4272\u20134290. https:\/\/doi.org\/10.1182\/blood-2001-12-0349","journal-title":"Blood"},{"issue":"24","key":"6947_CR5","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL et al (2014) Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123(24):3803\u20133810","journal-title":"Blood"},{"issue":"22","key":"6947_CR6","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1182\/blood.V114.22.2910.2910","volume":"114","author":"R Vaidya","year":"2009","unstructured":"Vaidya R et al (2009) Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera\u2014 Trends in Recent Years. Blood 114(22):2910. https:\/\/doi.org\/10.1182\/blood.V114.22.2910.2910","journal-title":"Blood"},{"issue":"9","key":"6947_CR7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881","journal-title":"Leukemia"},{"issue":"6","key":"6947_CR8","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larr\u00e1n","year":"2012","unstructured":"Alvarez-Larr\u00e1n A et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363\u20131369. https:\/\/doi.org\/10.1182\/blood-2011-10-387787","journal-title":"Blood"},{"issue":"10","key":"6947_CR9","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/jco.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224\u20132232. https:\/\/doi.org\/10.1200\/jco.2005.07.062","journal-title":"J Clin Oncol"},{"issue":"1","key":"6947_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R et al (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368(1):22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"issue":"6","key":"6947_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761\u2013770","journal-title":"J Clin Oncol"},{"issue":"5","key":"6947_CR12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/leu.2011.334","volume":"26","author":"F Passamonti","year":"2012","unstructured":"Passamonti F (2012) How to manage polycythemia vera. Leukemia 26(5):870\u2013874. https:\/\/doi.org\/10.1038\/leu.2011.334","journal-title":"Leukemia"},{"key":"6947_CR13","unstructured":"Lengfelder E et al (2023) Onkopedia Leitlinien: Polycythemia vera (PV)."},{"issue":"6","key":"6947_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00277-019-03654-6","volume":"98","author":"T Demuynck","year":"2019","unstructured":"Demuynck T et al (2019) Polycythemia vera and hydroxyurea resistance\/intolerance: a monocentric retrospective analysis. Ann Hematol 98(6):1421\u20131426. https:\/\/doi.org\/10.1007\/s00277-019-03654-6","journal-title":"Ann Hematol"},{"issue":"2","key":"6947_CR15","first-page":"143","volume":"83","author":"T Barbui","year":"1998","unstructured":"Barbui T, Finazzi G (1998) Treatment of polycythemia vera. Haematologica 83(2):143\u2013149","journal-title":"Haematologica"},{"issue":"5","key":"6947_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM et al (2015) Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426\u2013435","journal-title":"N Engl J Med"},{"issue":"3","key":"6947_CR17","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","volume":"7","author":"JJ Kiladjian","year":"2020","unstructured":"Kiladjian JJ et al (2020) Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 7(3):e226\u2013e237","journal-title":"Lancet Haematol"},{"issue":"1","key":"6947_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/s1470-2045(16)30558-7","volume":"18","author":"F Passamonti","year":"2017","unstructured":"Passamonti F et al (2017) Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol 18(1):88\u201399. https:\/\/doi.org\/10.1016\/s1470-2045(16)30558-7","journal-title":"Lancet Oncol"},{"issue":"7","key":"6947_CR19","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1016\/s2352-3026(22)00102-8","volume":"9","author":"F Passamonti","year":"2022","unstructured":"Passamonti F et al (2022) Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol 9(7):e480\u2013e492. https:\/\/doi.org\/10.1016\/s2352-3026(22)00102-8","journal-title":"Lancet Haematol"},{"issue":"4","key":"6947_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/cncr.28441","volume":"120","author":"S Verstovsek","year":"2014","unstructured":"Verstovsek S et al (2014) A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513\u2013520","journal-title":"Cancer"},{"issue":"7","key":"6947_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S et al (2016) Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 101(7):821\u2013829","journal-title":"Haematologica"},{"key":"6947_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113132","author":"P Sadjadian","year":"2020","unstructured":"Sadjadian P, Wille K, Griesshammer M (2020) Ruxolitinib-associated infections in polycythemia vera: review of the literature, clinical significance, and recommendations. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12113132","journal-title":"Cancers (Basel)"},{"issue":"5","key":"6947_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.23160","volume":"87","author":"E Antonioli","year":"2012","unstructured":"Antonioli E et al (2012) Hydroxyurea-related toxicity in 3,411 patients with Ph\u2019-negative MPN. Am J Hematol 87(5):552\u2013554. https:\/\/doi.org\/10.1002\/ajh.23160","journal-title":"Am J Hematol"},{"issue":"3","key":"6947_CR24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/ejh.14124","volume":"112","author":"A Theocharides","year":"2024","unstructured":"Theocharides A et al (2024) Ruxolitinib in patients with polycythemia vera resistant and\/or intolerant to hydroxyurea: European observational study. Eur J Haematol 112(3):379\u2013391. https:\/\/doi.org\/10.1111\/ejh.14124","journal-title":"Eur J Haematol"},{"issue":"19","key":"6947_CR25","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN et al (2023) Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol 41(19):3534\u20133544","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06947-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:48:20Z","timestamp":1781344100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06947-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6947"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06947-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees at each study site (leading ethics committee: \u201c\u00c4rztekammer Westfalen-Lippe und der Westf\u00e4lischen Wilhelms Universit\u00e4t\u201d responsible for the scientific expert (Prof. Griesshammer) was consulted before commencement of this study [positive vote on 13-May-2015]). The study was conducted in accordance with all local legal and regulatory requirements, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Patients, Guidelines for Good Clinical Practice, and the Declaration of Helsinki. All patients provided written informed consent prior to study inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable for patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Martin Griesshammer: Participated in advisory boards for and received grant support, consulting fees, honoraria, and meeting and travel support from Amgen, AOP Health, Eli Lilly, Novartis, BMS, AstraZeneca, and Janssen. Eyck von der Heyde: Received consulting fees and honoraria from Novartis, BMS, AstraZeneca, Ipsen, BeiGene, Iomedico, Boehringer Ingelheim and PierreFabre. Burkhard Schmidt: Participated in advisory boards and received honoraria and meeting and travel support from AbbVie, AOP, AstraZeneca, Beigene, BMS, Hexal, Incyte, Janssen, Menari Stemline, Novartis, Pfizer, Sanofi and SoBi Eva G\u00fcckel: Employee of Novartis Pharma, Germany. Volker Baum: Employee of Novartis Pharma, Germany The remaining authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}